Work

Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.e19535

Authors: Naveen Pemmaraju, Jingbo Yu, Shreekant Parasuraman, Dilan Paranagama, Jonathan Kish, Jay Visaria, Mukul Singhal, Srdan Verstovsek, Aaron Thomas Gerds

Institutions: The University of Texas MD Anderson Cancer Center, Incyte (United States), Cardinal Health (United States), Carelon Research (United States), Cleveland Clinic, Case Comprehensive Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3030489735

Cites:

Cited by: 5

Related to: 10